基于护理记录的利妥昔单抗输液反应主动监测规则的研究  

Study on the Active Monitoring Rule for Infusion Reactions to Rituximab Based on Nursing Records

作　　者：刘宏尉 刘宏莲 LIU Hong-wei;LIU Hong-lian(Department of Pharmacy,The First Affliated Hospital of Xiamen University,Xiamen 361000,China;the 900th Hospital of Joint Logistics Support Force of People's Liberation Army of China,Fuzhou 350000,China)

机构地区：[1]厦门大学附属第一医院药剂科,福建厦门361000 [2]中国人民解放军联勤保障部队第九〇〇医院健康医学科,福建福州350000

出　　处：《海峡药学》2025年第1期77-81,共5页Strait Pharmaceutical Journal

摘　　要：目的 应用中国医院药物警戒系统(CHPS)建立基于护理记录的利妥昔单抗导致输液反应的监测规则。方法 通过创建利妥昔单抗输液反应初始监测规则,回顾性分析2023年1月至2023年11月在我院住院期间使用利妥昔单抗患者的病历。结果 建立了贴合我院护师记录利妥昔单抗输液反应的监测规则,用于检测2023年1月至2023年11月547例使用利妥昔单抗的患者,检出预警病例76例,经人工判定输液反应实际为28例,利妥昔单抗相关输液反应实际发生率为5.12%(28/547),监测规则识别准确率36.84%(28/76),高于同期该药品不良反应(ADR)上报率10.71%(3/28)。结论 基于护理记录的利妥昔单抗输液反应主动监测规则具有良好的可行性,有助于提高不良反应上报率,提升患者用药安全。OBJECTIVE A rule for monitoring infusion reactions to rituximab based on nursing records was established using the China Hospital Pharmacovigilance System(CHPS).METHODS According to the preliminarily established monitoring rules for rituximab infusion reaction,a retrospective analysis was conducted herein on the medical records of inpatients administered with rituximab following their admission between January 2023 to November 2023.RESULTS Monitoring rules tailored to facilitate the documenting of rituximab infusion reactions by the hospital's nurses were employed to examine the 547 rituximab-infused patients from January 2023 to November 2023,and 76 cases with warning signs were detected.Infusion reactions to rituximab were finally identified in 28 patients after manual screening,with an incidence rate of 5.12%(28/547)and a detection rate of 36.8%(28/76)for the monitoring rule.recorded a 10.71%(3/28)increase in adverse drug reactions for this drug over the same reporting period.CONCLUSION The proactive monitoring rules on rituximab infusion reaction for nurses not only demonstrate satisfactory feasibility but also offer much utility by improving ADR reporting rate and medication safety.

关 键 词：输液反应 主动监测 利妥昔单抗 不良反应 

分 类 号：R969.3[医药卫生—药理学]